PROCEPT BioRobotics Announces Multi-Center, Real World Clinical Study Outcome

One-year Results from the OPEN WATER Trial is Published in the Journal of Clinical Medicine

PROCEPT BioRobotics Corporation, a surgical robotics company developing intelligent solutions to transform the field of urology, has announced that the safety and efficacy outcomes from a multi-center study of Aquablation therapy replicated those achieved in its pivotal clinical trials.

Aquablation therapy is a procedure for the treatment of benign prostatic hyperplasia (BPH), and is performed by the AquaBeam® Robotic System, the first FDA cleared, automated surgical robot for the treatment of this common condition.

“This study provided a very important validation of Aquablation therapy, as this is the first multi-center publication of outcomes in a commercial setting,” said Reza Zadno, president and CEO of PROCEPT BioRobotics. “These findings not only confirm the outcomes we saw in our landmark clinical trials but will also help encourage acceptance and adoption of Aquablation therapy as a new BPH treatment of choice for all prostates, in markets worldwide.”

OPEN WATER was a prospective, multicenter, single-arm, open-label clinical trial of the Aquablation procedure. One hundred and seventy-eight men with prostates sized between 20 and 150 cc were enrolled between September 2017 and December 2018 across five geographies, including Hamburg, Germany; Tauranga, New Zealand; Beirut, Lebanon; Melbourne, Australia; and Frimley, England. Open Water demonstrated large improvements at 12 months in symptom relief and peak urinary flow rates while preserving sexual function and urinary continence.

The study data, which were published in the Journal of Clinical Medicine, demonstrated large improvements at 12 months in symptom relief and peak urinary flow rates while preserving sexual function and urinary continence. Similar levels of symptom relief were seen independent of surgical experience. Moreover, the authors reported that no patient underwent a secondary procedure for recurrent BPH symptoms.

“As noted in our paper, the OPEN WATER study results indicate that the Aquablation procedure provides high levels of symptom relief, consistent with most resective techniques, but with an approximately eight times lower impact on sexual function,” said lead author Prof. Thorsten Bach, Asklepios Westklinikum Hamburg-Rissen. “The magnitude of symptom relief combined with such low rates of sexual dysfunction should give confidence to every urologist considering the adoption of Aquablation therapy in his or her practice.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides our readership with breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The ArthroFree system is the first FDA-cleared wireless camera for arthroscopy and general endoscopy, both areas of minimally invasive surgery. The system is designed to help surgeons work with aximum dexterity and focus.
The project, which was led by the University of Southern California, included large increases in representation among men of African, Hispanic and Asian ancestries, that were contributed in part by an ongoing collaboration between the U.S. Department of Veterans Affairs and DOE reports Argonne.
This innovative software turns smartphones into medical-grade stethoscopes, allowing people to capture, analyze, and share critical heart health data with medical personnel from the comfort of any location notes Sparrow BioAcoustics.
"Taewoong Medical becoming an Olympus group company is also a major milestone in our global growth strategy," said Henry Shin, CEO of STARmed. "We look forward to our products being made available to more patients through Olympus' global distribution network."
The company reports they have successfully met the six-month primary endpoint for the first-ever female patient implanted with the UroActive™ System, the first smart automated artificial urinary sphincter (AUS) to treat SUI.

By using this website you agree to accept Medical Device News Magazine Privacy Policy